IVERIC bio, Inc. (ISEE) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Parsippany, NJ, アメリカ. 現CEOは Glenn P. Sblendorio.
ISEE を有する IPO日 2013-09-25, 163 名の正社員, に上場 NASDAQ Global Select, 時価総額 $5.51B.
IVERIC bio, Inc. is a biopharmaceutical company focused on discovering and developing novel treatments for retinal diseases, particularly age-related macular degeneration and orphan inherited retinal diseases. The company's lead program, Zimura (an inhibitor of complement factor C5), is in Phase 3 clinical trials for geographic atrophy secondary to dry age-related macular degeneration, with earlier-stage candidates including STAR for leber congenital amaurosis and autosomal recessive stargardt disease, and IC-500, IC-100, and IC-200 targeting various inherited retinal conditions. IVERIC bio maintains a robust pipeline of programs in various clinical and preclinical stages, supported by gene therapy approaches including miniCEP290, miniABCA4, and miniUSH2A programs. Incorporated in 2007 and based in Parsippany, New Jersey, the company was formerly known as Ophthotech Corporation before rebranding in April 2019.
